Denosumab is an anti-receptor activator for nuclear factor-κB ligand antibody (anti-RANKL antibody) that, like BPs, has an inhibitory effect on osteoclasts and is used for malignant tumors and osteoporosis [27,28]. The gene discussed is TNFSF11; the disease is cancer.